| 1 |
Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports |
|
| | Niloofar Khoshnam-Rad, Azin Gheymati, Zahra Jahangard-Rafsanjani | | | Anti-Cancer Drugs. 2022; 33(1): e1 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Imatinib-induced pyoderma gangrenosum in a patient with chronic myeloid leukemia |
|
| | Andrea Giuseppe Faraci, Giovanni Genovese, Silvia Ferrucci, Angelo Valerio Marzano | | | Indian Journal of Dermatology, Venereology and Leprology. 2021; 87: 704 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Papel de las citocinas en el pioderma gangrenoso |
|
| | Víctor Alfonso Santos, William López, Carlos A. Cañas, Gabriel J. Tobón | | | Piel. 2019; 34(2): 94 | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Rituximab Causing Deep Ulcerative Suppurative Vaginitis/Pyoderma Gangrenosum |
|
| | Priya Selva-Nayagam,Gayle Fischer,Ian Hamann,Jack Sobel,Craig James | | | Current Infectious Disease Reports. 2015; 17(5) | | | [Pubmed] [Google Scholar] [DOI] | | | 5 |
Imatinib |
|
| | | | | Reactions Weekly. 2013; 1475(1): 22 | | | [Pubmed] [Google Scholar] [DOI] | | | 6 |
Sunitinib et pyoderma gangrenosum |
|
| | J.-L. Schmutz,P. Trechot | | | Annales de Dermatologie et de Vénéréologie. 2013; | | | [Pubmed] [Google Scholar] [DOI] | |
|
